🔗 Share this article

Given that the US continues making sweeping adjustments to its vaccine recommendations, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a US-based physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccinations in the global health crisis and has focused upon potential deaths after Covid immunization in her brief tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Vaccine Program

Public health authorities were set to reveal major revisions to the childhood vaccination calendar earlier this month, synchronizing the US with the Danish vaccine program, sources say – a significant shift that would put the US at odds with many the global community with insufficient data for improved outcomes. The announcement has been delayed until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to present at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this year.

A New Direction at the Agency

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine branches as Høeg and Prasad solidify control at the agency – and it suggests a renewed priority upon reevaluating already-approved immunizations at the FDA.

The new acting director has often pushed for ending some childhood shot schedules in the US so as to align more similar to Denmark's approach, a society with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

In her initial statements, she has continued to focus on immunizations – usually the domain of Dr. Prasad, chief of the FDA’s vaccine center – rather than pharmaceutical oversight.

Concerns Over Qualifications

The appointee has no obvious background in pharmaceutical research, regulation or administrative roles, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in running a large organization. She has no expertise in drug approvals.”

Former commissioners of the center would “be deeply familiar with legal statutes and the underlying principles of drug development”, commented Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who led the center have had.”

This division has an vast range of responsibilities at the FDA, she stated.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office clears numerous generic medications. There’s a biosimilars program, over-the-counter program and more, and each of these need to be looked after,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a significant administrative aspect to the position, which oversees over 5,000 employees. “It is a enormous management job, if you perform it correctly,” Woodcock added.

Response and Controversial Programs

When asked about questions about Høeg’s qualifications and whether this appointment represents increased cooperation among FDA leaders on immunizations, a press secretary responded that the “concerns are based on inaccurate assumptions”.

“This background is consistent with the duties of her position,” the representative stated, noting the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg assumes responsibility for the agency head's new priority voucher program, a contentious expedited drug-approval program that allegedly worried her predecessors. “By what process are these medications being selected for this expedited pathway? Who makes the choices?” Dr. Howard questioned. “There is a lot of confidentiality occurring at the FDA right now.”

In general, he said, “the Food and Drug Administration seems to be moving towards laxer regulations of all drugs, aside from shots.”

Documented Past Work on Vaccines

Regarding immunizations, Høeg has a clearer, if problematic, history, Howard observe. She published a research paper using unconfirmed public submissions to estimate the frequency of myocarditis after COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to suggest Covid vaccinations are riskier than they are.

Among her “wish list” for the new administration featured changing guidelines for novel immunizations and halting “non-essential” immunizations, she stated following the vote on a online show. At the FDA, Høeg has reportedly proposed barring teenage boys from obtaining Covid vaccines.

“She is an complete ideologue who begins with her preconceived notions and reverse-engineers to retrofit the evidence in a highly deceptive, dishonest way,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|